CT-XEROX-HOLDINGS
28.1.2021 15:02:31 CET | Business Wire | Press release
Xerox Holdings Corporation (NYSE: XRX) has expanded its growing software portfolio with the acquisition of CareAR , an augmented reality support platform company that provides real-time access to expertise for customers, employees, and field workers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005635/en/
With CareAR™ software, remote agents and experts can virtually see the situation and visually guide a solution using a suite of augmented reality tools via desktop, mobile, and smart glass devices, as if they were in-person.
Today, one-third of field service on-site calls require remote expert assistance to resolve issues but cannot effectively communicate the context of the situation. This causes delays, creating negative customer perception while risking loyalty and retention. Equipment downtime can be costly, running organizations between $300,000 and $5 million per hour, depending on the company’s size.1
“Our software solutions address some of the biggest needs for customers – content management, digital transformation and personalized communications. And now we’ve added enterprise augmented reality,” said Steve Bandrowczak, president and chief operations officer, Xerox. “By combining DocuShare® , XMPie and CareAR, we have a Software business that can together and apart support a wide range of clients’ needs.”
This expanded Software business will be led by Sam Waicberg, vice president and general manager of Digital Services for Xerox and former CareAR Co-founder and CEO prior to acquisition.
CareAR’s platform seamlessly integrates with workflow leader ServiceNow, ensuring an end-to-end approach to work orders, cases and incidents for full visibility and better troubleshooting.
“CareAR’s augmented reality software, which is integrated and certified with ServiceNow, helps customers remotely view and solve service issues,” says Michael Ramsey, vice president of Customer Workflow Product Management at ServiceNow. “Xerox’s acquisition of this technology can help drive further opportunities to modernize field service, customer support and IT services leveraging the power of the Now Platform and CareAR.”
Today, ServiceNow is collaborating with Deloitte to integrate the CareAR platform for ServiceNow® into the operations service systems and support workflows for joint clients.
“Xerox’s CareAR augmented reality platform provides us an ability to extend our market leading, industry-focused ServiceNow offerings.” said Asish Ramchandran, principal, Deloitte Consulting LLP. “CareAR represents the next mile in the digital transformation journey of organizations and together we have the ability to deliver next generation solutions that drive greater outcomes and value for our collective clients.”
CareAR is the latest addition to a series of solutions Xerox has launched to provide digital transformation tools to customers. These include automation and centralization solutions like DocuShare, a content management platform providing robust tools to automate processes and support cloud-enabled digital transformation; and XMPie, a flexible technology that allows customization and personalization of assets across customer touchpoints, both online and offline, for full marketing campaign integration.
In acknowledgement of the acquisition, CareAR is offering a free trial, found here: CareAR Trial . Offer valid starting January 28, 2021.
About Xerox
Xerox Holdings Corporation makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, the Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .
1 FieldPoint: The Numbers Behind First-Time Fix Rates You Should Know About
Note:
To receive RSS news feeds, visit https://www.news.xerox.com
. For open commentary, industry perspectives and views, visit
http://www.linkedin.com/company/xerox
, http://twitter.com/xerox
,
http://www.facebook.com/XeroxCorp
, https://www.instagram.com/xerox/
,
http://www.youtube.com/XeroxCorp
.
Xerox® and DocuShare® are trademarks of Xerox in the United States and/or other countries.
CareAR™ is a trademark of CareAR, Inc. in the United States and/or other countries.
ServiceNow® , the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc., in the United States and/or other countries.
Please see www.deloitte.com/us/about for a detailed description of their legal structure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005635/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom